It is becoming more and more difficult for the pharma industry to conduct business without being confronted with potential infringement to legislation. It is even more difficult considering the recent changes to the Pharma legislation and the interactions between IP, competition, regulatory and trade developments.
Our distinguished panel will provide you with practical and comprehensive information and insights from their own experiences on:
„XThe latest on the implementation of the EU pharma legislation
„XCrucial update on SPC provisions in different jurisdictions
„XThe impact of the new Bolar provision in the EU
„XThe extent of the various protections available for your IP rights and the different strategies available
„XHow to best to protect your market share
„XHow to combat tactics used by parallel importers
„XWhat the top pharma companies are doing to tackle the threats and opportunities presented by the EU enlargement
„XWhether data exclusivity is more valuable than patent protection
„XThe scope of the Paediatric Regulation, regulatory data protection and SPC extension
„XTo what extent industry regulatory practices constitute an infringement of competition law